Workflow
医药行业周报：医保竞价即将启动，关注三季报边际改善个股
Great Wall Securities·2024-11-04 07:19

Investment Rating - The report maintains an "Outperform" rating for the industry [1] Core Insights - The report highlights that the medical insurance bidding is about to start, and it suggests focusing on companies with marginal improvements in their Q3 reports [1] - The pharmaceutical sector has shown a recovery trend, with the CXO and medical device sectors experiencing a rebound in valuations [5] - The report emphasizes the potential for growth in new drug types such as peptides, ADCs, and oligonucleotides, indicating a robust growth space for leading CXO companies [5] Summary by Sections 1. Pharmaceutical Sector Performance - The pharmaceutical and biological sector increased by 3.11%, outperforming the CSI 300 index by 2.32 percentage points, ranking 16th among 31 sectors [8] - Sub-sectors such as medical services, medical devices, and traditional Chinese medicine II saw increases of 5.21%, 4.05%, and 3.39% respectively [8] 2. Key Stock Performers - Notable gainers in the chemical pharmaceutical sector include Koyuan Pharmaceutical (107.35%), Changshan Pharmaceutical (32.07%), and Shuangcheng Pharmaceutical (31.76%) [13] - In the traditional Chinese medicine II sector, Long Pharmaceutical Holdings (38.84%) and New Tian Pharmaceutical (21.69%) led the gains [16] - The biological products sector saw significant increases from Aopumai (30.42%) and Sihuan Bio (16.52%) [19] - In the medical commercial sector, Dajia Weikang (12.23%) and Rongfeng Holdings (10.26%) were among the top performers [22] - The medical device sector was led by *ST Dongyang (22.61%) and Maike Audi (17.01%) [25] - In medical services, Haocen Medical (27.13%) and Nuo Si Ge (25.76%) showed strong performance [28] 3. Company Earnings Reports - The report includes earnings data for several companies, such as: - Zhifei Biological reported a revenue of 22.786 billion yuan, down 41.98% year-on-year [39] - Yuyue Medical achieved a revenue of 6.028 billion yuan, a decrease of 9.53% year-on-year [40] - Enhua Pharmaceutical reported a revenue of 4.145 billion yuan, an increase of 13.39% year-on-year [41] - Zai Jian Pharmaceutical reported a revenue of 384 million yuan, an increase of 36.16% year-on-year [42]